Table 1.
Characteristics of all PGx recommendations and stratified by source of the recommendation.
| Strata | All PGx Recs (n = 606) | Source of PGx Recs | P value* | ||
|---|---|---|---|---|---|
| CPG (n = 172) | CPIC (n = 66) | FDA (n = 368) | |||
| # unique drugs | 267 | 91 | 46 | 254 | n/a |
| # unique drug–gene pairs | 433 | 172 | 66 | 368 | n/a |
| Germline vs. somatic vs. pathogen | |||||
| Germline | 353 (58.3%) | 50 (29.1%) | 66 (100.0%) | 237 (64.4%) | <0.001 |
| Somatic | 250 (41.3%) | 119 (69.2%) | 0 (0.0%) | 131 (35.6%) | |
| Pathogen | 3 (0.5%) | 3 (1.7%) | 0 (0.0%) | 0 (0.0%) | |
| Pharmacokinetic (PK) vs. pharmacodynamic (PD) | |||||
| PK | 190 (31.4%) | 22 (12.8%) | 40 (60.6%) | 128 (34.8%) | <0.001 |
| PD | 416 (68.7%) | 150 (87.2%) | 26 (39.4%) | 240 (65.2%) | |
| Genetic variant vs. gene/protein expression | |||||
| Genetic variant | 484 (79.9%) | 111 (64.5%) | 66 (100.0%) | 307 (83.4%) | <0.001 |
| Gene/protein expression | 122 (20.1%) | 61 (35.5%) | 0 (0.0%) | 61 (16.6%) | |
| Therapeutic area (TA) | |||||
| Anesthetics | 38 (6.3%) | 14 (8.1%) | 14 (21.2%) | 10 (2.7%) | <0.001 |
| Anti-infectives | 19 (3.1%) | 3 (1.7%) | 1 (1.5%) | 15 (4.1%) | |
| Antivirals | 26 (4.3%) | 4 (2.3%) | 6 (9.1%) | 16 (4.4%) | |
| Cardiovascular | 43 (7.1%) | 7 (4.1%) | 6 (9.1%) | 30 (8.2%) | |
| Hematology | 79 (13.0%) | 32 (18.6%) | 4 (6.1%) | 43 (11.7%) | |
| Neurology | 33 (5.5%) | 2 (1.2%) | 5 (7.6%) | 26 (7.1%) | |
| Oncology | 217 (35.8%) | 95 (55.2%) | 3 (4.6%) | 119 (32.3%) | |
| Other TAs | 62 (10.2%) | 2 (1.2%) | 6 (9.1%) | 54 (14.7%) | |
| Psychiatry | 65 (10.7%) | 10 (5.8%) | 18 (27.3%) | 37 (10.1%) | |
| Pulmonary | 12 (2.0%) | 2 (1.2%) | 1 (1.5%) | 9 (2.5%) | |
| Rheumatology | 12 (2.0%) | 1 (0.6%) | 2 (3.0%) | 9 (2.5%) | |
| Recommendation category | |||||
| Indication | 194 (32.0%) | 102 (59.3%) | 0 (0.0%) | 92 (25.0%) | <0.001 |
| Contraindication | 29 (4.8%) | 0 (0.0%) | 16 (24.2%) | 13 (3.5%) | |
| Not recommended | 82 (13.5%) | 22 (12.8%) | 39 (59.1%) | 21 (5.7%) | |
| Dose adjustment | 38 (6.3%) | 2 (1.2%) | 8 (12.1%) | 28 (7.6%) | |
| Use with caution | 65 (10.7%) | 0 (0.0%) | 0 (0.0%) | 65 (17.7%) | |
| No dose adjustment | 17 (2.8%) | 2 (1.2%) | 0 (0.0%) | 15 (4.1%) | |
| Informational (none) | 181 (29.9%) | 44 (25.6%) | 3 (4.6%) | 134 (36.4%) | |
| Actionable | 408 (67.3%) | 126 (73.3%) | 63 (95.5%) | 219 (59.5%) | <0.001 |
| Routine screening | 206 (34.0%) | 104 (60.5%) | n/a | 102 (27.8%) | <0.001 |
| Quantitative characteristics | |||||
| Years since publication | 0.75 (0.19–1.77) | 0.19 (0.19–0.81) | 2.46 (0.58–4.04) | 0.82 (0.42–1.77) | <0.001 |
| Number of variants | 0 (0–2) | 1 (0–2) | 11.5 (6–57) | 0 (0–1) | <0.001 |
CPG clinical practice guideline, CPIC Clinical Pharmacogenetics Implementation Consortium, FDA U. S. Food & Drug Administration, PGx pharmacogenetics, Recs recommendations.
Data are presented as count (%) or median (interquartile range).
*P values are for the comparison of CPG vs. CPIC vs. FDA. Bolded P values indicate P < 0.05.